Table 6 Summary of the outcome of other studies conducted with a combination of different cellular products
From: Cell therapies for autism spectrum disorder: a systematic review of clinical applications
| Â | Lv et al. [51] | Bradstreet et al. [10] | ||
|---|---|---|---|---|
CB-TNC group | CB-TNC/UC-MSC Combination group | |||
CARS | Improved | Improved significantly | - | |
ATEC | - | - | Improved significantly | |
CGI-SI | Improved significantly | Improved significantly | - | |
CGI-EI | Improved significantly | Improved significantly | - | |
CGI-GI | Improved significantly | Improved significantly | - | |
ABC | Irritability | No change | No change | Improved significantly |
Lethargy | No change | Improved significantly | ||
Stereotypic behavior | Improved significantly | Improved significantly | ||
Hyperactivity | No change | No change | ||
Inappropriate speech | No change | No change | ||
Total score | Improved significantly | Improved significantly | ||
Major adverse events | None | None | None | |